{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:37:13Z","timestamp":1768595833349,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.semarthrit.2025.152651","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:33:39Z","timestamp":1738334019000},"page":"152651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Refractory cutaneous ulcers in anti-MDA5 dermatomyositis were not associated with rapidly progressive interstitial lung disease, and responded to tadalafil"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-9307","authenticated-orcid":false,"given":"Yongpeng","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2025.152651_bib0001","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/1744666X.2019.1699059","article-title":"Current understanding and recent advances in myositisspecific and -associated autoantibodies detected in patients with dermatomyositis","volume":"16","author":"Gono","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semarthrit.2025.152651_bib0002","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152651_bib0003","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMicm1816147","article-title":"Cutaneous ulcerations in anti-MDA5 dermatomyositis","volume":"381","author":"Charrow","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152651_bib0004","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1097\/RHU.0000000000001114","article-title":"Successful treatment of Anti-MDA5 dermatomyositis associated cutaneous digital pulp ulcerations with hyperbaric oxygen therapy","volume":"26","author":"Jeter","year":"2020","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152651_bib0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/idoj.IDOJ_72_17","article-title":"Reticulated ulcerations, panniculitis and violaceous plaques in a 46-year-old woman","volume":"9","author":"Agull\u00f3","year":"2018","journal-title":"Indian Dermatol Online J"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152651_bib0006","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jamadermatol.2017.5462","article-title":"Bosentan for cutaneous ulcers in anti-MDA5 dermatomyositis","volume":"154","author":"Combalia","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152651_bib0007","first-page":"e1","article-title":"Cutaneous ulcers in anti-MDA5 dermatomyositis successfully treated with sildenafil","volume":"182","author":"Collantes-Rodr\u00edguez","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2025.152651_bib0008","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152651_bib0009","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: classification of dermatomyositis, Amsterdam, The Netherlands, 14-16 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152651_bib0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.42308","article-title":"Identification of Three Different Phenotypes in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Patients: implications for Prediction of Rapidly Progressive Interstitial Lung Disease","volume":"75","author":"Xu","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152651_bib0011","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjd.15140","article-title":"The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists","volume":"176","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152651_bib0012","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2020.01.002","article-title":"The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review","volume":"50","author":"Ahmed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152651_bib0013","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/joim.13607","article-title":"Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis","volume":"293","author":"Jin","year":"2023","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152651_bib0014","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","article-title":"Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review","volume":"51","author":"Muro","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152651_bib0015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22498","article-title":"Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease","volume":"67","author":"Narang","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2025.152651_bib0016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140)","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152651_bib0017","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000346573","article-title":"Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis","volume":"225","author":"Clottu","year":"2012","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152651_bib0018","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000506668","article-title":"Acral cutaneous ulcerations and livedo reticularis with rapidly progressive interstitial lung disease in anti-MDA5 antibody-positive classical dermatomyositis","volume":"12","author":"Wongjirattikarn","year":"2020","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.semarthrit.2025.152651_bib0019","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar2186","article-title":"How does endothelial cell injury start? The role of endothelin in systemic sclerosis","volume":"9","author":"Abraham","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152651_bib0020","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152651_bib0021","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152651_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1753465812463627","article-title":"Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension","volume":"7","author":"Udeoji","year":"2013","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.semarthrit.2025.152651_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis With Anti-MDA5 Antibodies: bioclinical Features, Pathogenesis and Emerging Therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152651_bib0024","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3988\/jcn.2020.16.1.160","article-title":"Refractory Digital Ulcers Treated by Botulinum Toxin and Endothelin Receptor-1 Antagonist in Anti-MDA5-Antibody-Positive Dermatomyositis","volume":"16","author":"Min","year":"2020","journal-title":"J Clin Neurol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152651_bib0025","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00296-014-3025-z","article-title":"Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon","volume":"34","author":"Kamata","year":"2014","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152651_bib0026","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","volume":"80","author":"Kim","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152651_bib0027","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjd.21252","article-title":"Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib","volume":"187","author":"Fischer","year":"2022","journal-title":"Br J Dermatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:52:30Z","timestamp":1741099950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"alternative-id":["S0049017225000228"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152651","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory cutaneous ulcers in anti-MDA5 dermatomyositis were not associated with rapidly progressive interstitial lung disease, and responded to tadalafil","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152651"}}